But it won't work for Meagan. It targets a genetic mutation she does not have. It does illustrate the direction cancer drug research is heading - moving from slash, burn and poison to smarter targeting of individual mutations.
http://www.webmd.com/melanoma-skin-cancer/news/20110817/zelboraf-approved-for-late-stage-melanoma
No comments:
Post a Comment